Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab with Anlotinib and Docetaxel in CPI-Experienced Advanced NSCLC
NCT05816499Phase 2Active, not recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Started Feb 2023; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05816499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816499.